FDA Recall: BD ChloraPrep™ Clear Applicators Linked to Possible Aspergillus Contamination

If you or a family member recently had surgery or had an intravenous (IV) line or catheter placed, a new FDA-linked recall may be worth asking about. BD is recalling specific lots of skin-prep applicators used before procedures because of a potential for Aspergillus penicillioides contamination under certain conditions.

The recall does not mean everyone who used these products will develop infection. But if you’re higher-risk—especially if you’re immunocompromised—it’s reasonable to contact your care team for clarity and to watch for concerning symptoms after your procedure.

Quick context: what FDA says was recalled

FDA posted a recall notice for BD on June 08, 2026, following the company’s announcement on June 06, 2026. FDA’s recall is lot-specific and applies to:

ChloraPrep™ Clear (single sterile applicators, 1 mL)
FREPP™ Clear (single sterile applicators, 1.5 mL)

FDA frames the concern as potential fungal contamination that could lead to serious infection if introduced during an invasive procedure.

What could happen if contamination gets introduced

In its recall notice, FDA explains that contamination of skin-prep products with Aspergillus penicillioides may lead to serious systemic infection, including sepsis, if the fungus is introduced during a procedure.

FDA also describes how risk could play out in real-world care:

Intravascular catheter placement: If contamination enters the bloodstream, clinicians may need to evaluate whether a catheter removal or other interventions are necessary.
Surgical sites: Infection at a surgical site can require additional medical care and may involve antifungal treatment in confirmed cases.

What’s known: the concern is tied to specific lots and certain conditions identified by the manufacturer and FDA. What’s not known (for the public): how many patients were exposed and the actual probability of infection after exposure.

Who should be more concerned

Aspergillosis risk is generally higher in people with weakened immune systems and certain lung conditions. CDC notes that most people who breathe in Aspergillus spores do not get sick, but higher-risk patients are more likely to develop illness.

Because these products are used as skin antisepsis before procedures, the groups to consider asking extra questions about include:

IV/intravascular catheter placement
Surgery or other procedures that create an entry point for infection
Care settings where immunocompromised patients are treated

What readers can do now (practical next steps)

Ask the facility/care team. If you recently had a procedure (or you’re a caregiver for someone who did), call the clinic or hospital unit and ask whether the procedure location used any recalled lots.
Don’t assume your care used (or didn’t use) the recalled product. Recalls are lot-specific, and facilities may have different inventory at different times.
Have your timeline ready. Be ready to share the approximate procedure date and the type of procedure (for example, “central line placement” or “surgery”), so staff can check lot records.

If you’re immunocompromised, it’s especially reasonable to ask for an update about whether any recalled lots were used.

After a recent procedure: what to watch for

Symptoms of aspergillosis can vary by the type of infection and where it spreads. CDC describes invasive aspergillosis as serious and lists possible symptoms such as:

Fever
Chest pain
Cough
Coughing up blood
Shortness of breath

When to seek urgent medical evaluation

Seek urgent medical evaluation (or emergency care, depending on severity) if you develop severe or rapidly worsening symptoms after a procedure—particularly if you’re high-risk. Because symptoms can overlap with many other conditions, the key point is to get prompt assessment so clinicians can evaluate you.

Also contact your care team for guidance if you’re concerned that a recalled lot could have been used.

The bottom line

FDA says BD recalled specific lots of ChloraPrep™ Clear and FREPP™ Clear applicators due to possible Aspergillus contamination.
BD has not reported confirmed outcomes for the public in the way a confirmed outbreak would be documented (the recall is a precaution tied to lot-specific risk).
High-risk patients—especially those who are immunocompromised—should consider asking their facility whether any recalled lots were used.
After a procedure, get urgent evaluation for severe or worsening symptoms such as fever, chest pain, cough, coughing up blood, or shortness of breath.

Key sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.